In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains.

@article{Oleksijew1998InVE,
  title={In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains.},
  author={Anatol X Oleksijew and J A Meulbroek and Patty J Ewing and Kym Jarvis and Michael J. Mitten and Lebron Paige and Ann Tovcimak and M Nukkula and Daniel Chu and Jeff D. Alder},
  journal={Antimicrobial agents and chemotherapy},
  year={1998},
  volume={42 10},
  pages={2674-7}
}
Current therapy for pulmonary tuberculosis involves 6 months of treatment with isoniazid, pyrazinamide, rifampin, and ethambutol or streptomycin for reliable treatment efficacy. The long treatment period increases the probability of noncompliance, leading to the generation of multidrug-resistant isolates of Mycobacterium tuberculosis. A treatment option that significantly shortened the course of therapy, or a new class of antibacterial effective against drug-resistant M. tuberculosis would be… CONTINUE READING
3 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…